167 related articles for article (PubMed ID: 12127315)
21. Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.
Gugerell A; Sorgenfrey D; Laggner M; Raimann J; Peterbauer A; Bormann D; Suessner S; Gabriel C; Moser B; Ostler T; Mildner M; Ankersmit HJ
Blood Transfus; 2020 Jan; 18(1):30-39. PubMed ID: 30865581
[TBL] [Abstract][Full Text] [Related]
22. The band III ligand dipyridamole protects human RBCs during photodynamic treatment while extracellular virus inactivation is not affected.
Besselink GA; Van Engelenburg FA; Korsten HG; Blokker DE; Lagerberg JW; Brand A; De Korte D; Verhoeven AJ
Transfusion; 2002 Jun; 42(6):728-33. PubMed ID: 12147025
[TBL] [Abstract][Full Text] [Related]
23. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
24. Viral inactivation of human bone tissue using supercritical fluid extraction.
Fages J; Poirier B; Barbier Y; Frayssinet P; Joffret ML; Majewski W; Bonel G; Larzul D
ASAIO J; 1998; 44(4):289-93. PubMed ID: 9682954
[TBL] [Abstract][Full Text] [Related]
25. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
27. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
28. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
29. Arginine-enveloped virus inactivation and potential mechanisms.
Meingast C; Heldt CL
Biotechnol Prog; 2020 Mar; 36(2):e2931. PubMed ID: 31622532
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis.
Vollenbroich D; Ozel M; Vater J; Kamp RM; Pauli G
Biologicals; 1997 Sep; 25(3):289-97. PubMed ID: 9324997
[TBL] [Abstract][Full Text] [Related]
31. Measuring the effectiveness of gaseous virus disinfectants.
Knotzer S; Kindermann J; Modrof J; Kreil TR
Biologicals; 2015 Nov; 43(6):519-23. PubMed ID: 26260690
[TBL] [Abstract][Full Text] [Related]
32. Physiochemical properties of enveloped viruses and arginine dictate inactivation.
Meingast CL; Joshi PU; Turpeinen DG; Xu X; Holstein M; Feroz H; Ranjan S; Ghose S; Li ZJ; Heldt CL
Biotechnol J; 2021 Jul; 16(7):e2000342. PubMed ID: 33877739
[TBL] [Abstract][Full Text] [Related]
33. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization.
Wagner SJ; Robinette D; Storry J; Chen XY; Shumaker J; Benade L
Transfusion; 1994 Jun; 34(6):521-6. PubMed ID: 8023394
[TBL] [Abstract][Full Text] [Related]
34. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
35. Virus removal or inactivation in hemoglobin solutions by ultrafiltration or detergent/solvent treatment.
Bechtel MK; Bagdasarian A; Olson WP; Estep TN
Biomater Artif Cells Artif Organs; 1988; 16(1-3):123-8. PubMed ID: 2846096
[TBL] [Abstract][Full Text] [Related]
36. New methods for inactivation of lipid-enveloped and non-enveloped viruses.
Miekka SI; Busby TF; Reid B; Pollock R; Ralston A; Drohan WN
Haemophilia; 1998 Jul; 4(4):402-8. PubMed ID: 9873761
[TBL] [Abstract][Full Text] [Related]
37. Strategies for evaluation of enveloped virus inactivation in red cell concentrates using hypericin.
Prince AM; Pascual D; Meruelo D; Liebes L; Mazur Y; Dubovi E; Mandel M; Lavie G
Photochem Photobiol; 2000 Feb; 71(2):188-95. PubMed ID: 10687393
[TBL] [Abstract][Full Text] [Related]
38. Validation of model virus removal and inactivation capacity of an erythropoietin purification process.
Pérez M; Rodríguez E; Rodríguez M; Paez R; Ruibal I; Noa E; García O; Moya G; Martínez M; Marcelo J; Martínez A; Dubal M; Navea L; Valdés R
Biologicals; 2011 Nov; 39(6):430-7. PubMed ID: 21982851
[TBL] [Abstract][Full Text] [Related]
39. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products.
Reid KG; Cuthbertson B; Jones AD; McIntosh RV
Vox Sang; 1988; 55(2):75-80. PubMed ID: 3142151
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of eco-friendly zwitterionic detergents for enveloped virus inactivation.
Conley L; Tao Y; Henry A; Koepf E; Cecchini D; Pieracci J; Ghose S
Biotechnol Bioeng; 2017 Apr; 114(4):813-820. PubMed ID: 27800626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
